Article
Pathology
Julien Dagher, Angelique Brunot, Bertrand Evrard, Solene-Florence Kammerer-Jacquet, Marion Beaumont, Laurence Cornevin, Fanny Derquin, Gregory Verhoest, Karim Bensalah, Alexandra Lespagnol, Frederic Dugay, Marc-Antoine Belaud-Rotureau, Frederic Chalmel, Nathalie Rioux-Leclercq
Summary: Metastatic evolution in clear cell renal cell carcinoma is complex, with tumor heterogeneity resulting from clonal evolution playing a role in metastatic dissemination. Using an integrative multiomics strategy, it was found that all sites were heterogeneous and polyclonal, with each tumor site containing two aggressive subclonal populations.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Review
Medicine, General & Internal
Anna Pliszka, Sebastian Rajda, Agata Wawrzyniak, Jerzy Walocha, Michal Polguj, Grzegorz Wysiadecki, Edward Clarke, Michal Golberg, Michal Zarzecki, Krzysztof Balawender
Summary: This systematic review aimed to summarize current knowledge on testicular metastasis of renal cell carcinoma (RCC). It was found that approximately one-third of RCC cases are recognized in its metastatic stage. Testicular metastasis suggests advanced disease stage, with swelling and enlargement of the affected testis as the main symptoms. Understanding the possibility of such RCC metastases is crucial for making an appropriate diagnosis and implementing timely treatment in the management of neoplastic disease.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gregoire Cazalas, Clement Klein, Gilles Piana, Eric De Kerviler, Afshin Gangi, Philippe Puech, Cosmina Nedelcu, Remi Grange, Xavier Buy, Marc-Antoine Jegonday, Pierre Bigot, Charles Karim Bensalah, Victor Gaillard, Geraldine Pignot, Philippe Paparel, Lionel Badet, Clement Michiels, Jean Christophe Bernhard, Olivier Rouviere, Nicolas Grenier, Clement Marcelin
Summary: Percutaneous-guided thermal ablation and robotic-assisted partial nephrectomy are effective treatments for T1b renal cancer; however, thermal ablation has a higher local recurrence rate.
EUROPEAN RADIOLOGY
(2023)
Letter
Medicine, General & Internal
Aparna Sharma, Ranjit K. Sahoo, Atul Batra, Archie Bleyer, Toni K. Choueiri, Thomas Powles
Summary: Adding adjuvant pembrolizumab after nephrectomy can significantly improve disease-free survival in patients with renal-cell carcinoma, but there are concerns regarding the arbitrary duration of 12 months of adjuvant treatment. Many patients discontinued treatment due to adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Urology & Nephrology
Ekaterina Laukhtina, Benjamin Pradere, David D'Andrea, Giuseppe Rosiello, Stefano Luzzago, Angela Pecoraro, Carlotta Palumbo, Sophie Knipper, Pierre Karakiewicz, Vitaly Margulis, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Keiichiro Mori, Victor M. Schuettfort, Dmitry Enikeev, Shahrokh F. Shariat
Summary: In metastatic renal cell carcinoma patients, a preoperative high SII value (>710) is independently associated with unfavorable clinical outcomes, especially in those with intermediate risk mRCC and increased BMI.
MINERVA UROLOGY AND NEPHROLOGY
(2022)
Article
Medicine, General & Internal
Muhammad Ammar B. Hamid, Aasim Sehbai, Shahan Tariq, Sana Ullah
Summary: Renal cell carcinoma is a common malignancy in elderly males, with metastatic spread often involving the lung, bone, liver, and brain. While most cases present within five years of nephrectomy, it is important to consider relapsed metastatic renal cancer even decades after surgical removal.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Surgery
Zhenhua Liu, Zhenyu Yang, Jibin Li, Zefu Liu, Nan Ma, Peng Chen, Xing Bi, Zhiyong Li, Pei Dong, Hui Han, Xiaobo He, Xiaopeng Mao, Shengjie Guo
Summary: This retrospective study analyzed data of pT3aN0M0 renal cell carcinoma patients and found that PN may have a survival benefit compared to RN, especially in cases with tumor size 0-4 cm. Survival outcomes were similar between PN and RN in cases with tumor size 4-7 cm. These findings suggest that PN could be a viable alternative choice for T3aN0M0 RCC, particularly in smaller tumors.
ASIAN JOURNAL OF SURGERY
(2023)
Article
Cell Biology
Zhipeng Xu, Min Liu, Jin Wang, Kai Liu, Liuyu Xu, Demin Fan, Hui Zhang, Wenxin Hu, Dan Wei, Jianning Wang
Summary: The MYH9 gene is commonly upregulated in clear cell renal cell carcinoma (ccRCC) and its overexpression predicts poor prognosis. Knockdown of MYH9 inhibits the proliferative and metastatic potentials of ccRCC cells, while overexpression enhances these properties. Furthermore, MYH9 plays vital roles through the AKT signaling pathway and determines the response of ccRCC cells to sunitinib treatment.
CELL DEATH DISCOVERY
(2022)
Article
Oncology
Margaret F. Meagher, Maria C. Mir, Andrea Minervini, Maximilian Kriegmair, Matthias Heck, Francesco Porpiglia, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Maurizio D'Anna, Alessandro Veccia, Eduard Roussel, Francesco Claps, Carlotta Palumbo, Michele Marchioni, Jonathan Afari, Cesare Saitta, Franklin Liu, Jose Rubio, Riccardo Campi, Andrea Mari, Thomas Amiel, Enrico Checcucci, Mireia Musquera, Georgi Guruli, Nicola Pavan, Maarten Albersen, Alessandro Antonelli, Tobias Klatte, Riccardo Autorino, Rana R. McKay, Ithaar H. Derweesh
Summary: The study aimed to determine the accuracy of a proposed two-tier re-classification of the M domain in the TNM staging of RCC. The analysis of patients from the REMARCC database showed that the M2 classification was an independent risk factor for worsened mortality. Comparisons between M1 and M2 groups demonstrated significant differences in overall survival and cancer-specific survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yidan Lou, Kaibo Guo, Song Zheng
Summary: This report describes a rare case of renal cell carcinoma metastasis to the pancreas, with isolated pancreatic metastasis being even rarer. The patient responded well to surgery and systemic therapy, and showed no recurrence after 2 years. In conclusion, isolated pancreatic metastasis of renal cell carcinoma is a distinct subtype with unique clinical characteristics, which may be explained by underlying molecular mechanisms. Surgery and systemic therapy offer survival benefits to patients with isolated pancreatic metastasis, although recurrence should be closely monitored.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
T. K. Choueiri, T. Powles, M. Burotto, B. Escudier, M. T. Bourlon, B. Zurawski, V. M. Oyervides Juarez, J. J. Hsieh, U. Basso, A. Y. Shah, C. Suarez, A. Hamzaj, J. C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J. P. Feregrino, J. Zolnierek, D. Pook, E. R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M. A. Maurer, B. Simsek, F. Ejzykowicz, G. M. Schwab, A. B. Apolo, R. J. Motzer
Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata, Satoshi Sato, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
Summary: This study investigated primary resistance to NIVO+IPI as a first-line treatment in patients with metastatic renal cell carcinoma (mRCC). It found that approximately 20% of patients developed primary resistant disease (PRD) with worse survival rates. Lymph node metastasis (LNM) was identified as an independent risk factor for PRD.
Review
Oncology
Rocco S. Flammia, Benedikt Hoeh, Lukas Hohenhorst, Gabriele Sorce, Francesco Chierigo, Andrea Panunzio, Zhe Tian, Fred Saad, Costantino Leonardo, Alberto Briganti, Alessandro Antonelli, Carlo Terrone, Shahrokh F. Shariat, Markus Graefen, Felix K. H. Chun, Francesco Montorsi, Michele Gallucci, Pierre I. Karakiewicz
Summary: Based on a retrospective study, our findings suggest that 36% of patients treated with adjuvant pembrolizumab may require rechallenge within 10 years, while 22% of patients may die from other causes during this period. These percentages should be carefully considered before the routine use of adjuvant pembrolizumab, especially in the absence of proven overall survival benefits.
SEMINARS IN ONCOLOGY
(2022)
Article
Oncology
Yun Peng, Shiqiang Dong, Yuxuan Song, Dingkun Hou, Lili Wang, Bowen Li, Haitao Wang
Summary: This study identified key immune-related genes and hub genes associated with sunitinib and immune infiltration in clear cell RCC (ccRCC), providing insights into sunitinib resistance and potential biomarkers or drug targets for ccRCC.
Article
Cardiac & Cardiovascular Systems
Julien Rossi, Roberto Luigi Cazzato, Pierre de Marini, Pierre Auloge, Pierre-Alexis Autrusseau, Danoob Dalili, Thibault Tricard, Baptiste Poussot, Julien Garnon, Herve Lang, Afshin Gangi
Summary: The study retrospectively investigated the safety and oncological outcomes of cryoablation for residual/recurring renal cell carcinoma in the ipsilateral kidney following partial nephrectomy. The results showed that cryoablation is safe and results in high estimates of local tumor progression-free survival.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
(2022)
Article
Genetics & Heredity
Yasmin Bylstra, Sonia Davila, Weng Khong Lim, Ryanne Wu, Jing Xian Teo, Sylvia Kam, Tamra Lysaght, Steve Rozen, Bin Tean Teh, Khung Keong Yeo, Stuart A. Cook, Patrick Tan, Saumya Shekhar Jamuar
NPJ GENOMIC MEDICINE
(2019)
Article
Oncology
Annika Herlemann, Huei-Chung Huang, Ridwan Alam, Jeffery J. Tosoian, Hyung L. Kim, Eric A. Klein, Jeffry P. Simko, June M. Chan, Brian R. Lane, John W. Davis, Elai Davicioni, Felix Y. Feng, Peter McCue, Hyun Kim, Robert B. Den, Tarek A. Bismar, Peter R. Carroll, Matthew R. Cooperberg
PROSTATE CANCER AND PROSTATIC DISEASES
(2020)
Article
Oncology
John L. Gore, Marguerite du Plessis, Jingbin Zhang, Darlene Dai, Darby J. S. Thompson, Lawrence Karsh, Brian Lane, Michael Franks, David Y. T. Chen, Fernando J. Bianco, Gordon Brown, William Clark, Adam S. Kibel, Hyung Kim, William Lowrance, Murugesan Manoharan, Paul Maroni, Scott Perrapato, Paul Sieber, Edouard J. Trabulsi, Robert Waterhouse, Daniel E. Spratt, Elai Davicioni, Yair Lotan, Daniel W. Lin
PRACTICAL RADIATION ONCOLOGY
(2020)
Article
Endocrinology & Metabolism
Austin Yeon, Yanping Wang, Hengchen Su, Eric M. Lo, Hyung L. Kim
Article
Genetics & Heredity
Jing Han Hong, Siao Ting Chong, Po-Hsien Lee, Jing Tan, Hong Lee Heng, Nur Diana Binte Ishak, Sock Hoai Chan, Bin Tean Teh, Joanne Ngeow
NPJ GENOMIC MEDICINE
(2020)
Article
Oncology
Paige K. Kuhlmann, Michelle Chen, Michael Luu, Aurash Naser-Tavakolian, Devin N. Patel, Hyung L. Kim, Rola Saouaf, Timothy J. Daskivich
Summary: Black race and PSA density were associated with presence of MRI-invisible prostate cancer. Systematic biopsy detection of MRI-invisible tumors upgraded patients from no disease to GG2+ disease and from GG1 to GG2+ disease at different rates for non-Black and Black men.
PROSTATE CANCER AND PROSTATIC DISEASES
(2021)
Article
Urology & Nephrology
Eric M. Lo, Hyung L. Kim
UROLOGIC CLINICS OF NORTH AMERICA
(2021)
Article
Medicine, General & Internal
Paul J. Brindley, Melinda Bachini, Sumera I. Ilyas, Shahid A. Khan, Alex Loukas, Alphonse E. Sirica, Bin Tean Teh, Sopit Wongkham, Gregory J. Gores
Summary: Cholangiocarcinoma is a highly lethal adenocarcinoma of the hepatobiliary system that can be associated with liver fluke infection but often has no identifiable cause. This Primer reviews the epidemiology, pathophysiological mechanisms, diagnosis and management of cholangiocarcinoma, and highlights the patient experience and future directions.
NATURE REVIEWS DISEASE PRIMERS
(2021)
Article
Oncology
Yanping Wang, Sungyong You, Shengchen Su, Austin Yeon, Eric M. Lo, Sungjin Kim, James L. Mohler, Michael R. Freeman, Hyung L. Kim
Summary: Lowering serum cholesterol enhances antitumor immune response in prostate cancer patients by improving CD8(+) T-cell memory.
CLINICAL CANCER RESEARCH
(2022)
Article
Pathology
Jian Yuan Goh, Chik Hong Kuick, Masahiro Sugiura, Sze Jet Aw, Manli Zhao, Hongfeng Tang, Sandini Gunaratne, Fucun Zhu, Lin Cai, Bin Tean Teh, Paul S. Thorner, Kenneth Tou En Chang
Summary: This study analyzed two cases of CCSK and one case of PMMTI using Archer FusionPlex technology and found a novel BCOR ITD mutation, which is unusually long and difficult to detect using typical primer design strategies and DNA sequencing.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2022)
Article
Oncology
Jun Gong, Edwin M. Posadas, Neil Bhowmick, Hyung L. Kim, Timothy J. Daskivich, Amit Gupta, Howard M. Sandler, Mitchell Kamrava, Zachary S. Zumsteg, Stephen J. Freedland, Robert A. Figlin
Summary: Mutations in the DNA-damage repair (DDR) pathway can sensitize cancer cells to PARP inhibitors, with two of these agents currently approved for the treatment of DDR-altered metastatic castrate-resistant prostate cancer (mCRPC). PARP inhibitors are being integrated into advanced prostate cancer clinical practice for treatment-refractory settings.
Article
Oncology
William A. Hall, Nick Fishbane, Yang Liu, Melody J. Xu, Elai Davicioni, Brandon A. Mahal, Robert B. Den, Robert T. Dess, William C. Jackson, Anthony C. Wong, Edward M. Schaeffer, R. Jeffrey Karnes, Peter R. Carroll, Matthew R. Cooperberg, Tarek A. Bismar, Hyung L. Kim, Eric A. Klein, John W. Davis, Ashley E. Ross, Jeffrey J. Tosoian, Todd M. Morgan, Rohit Mehra, Simpa S. Salami, Paul L. Nguyen, Colleen A. F. Lawton, Daniel E. Spratt, Felix Feng
JCO PRECISION ONCOLOGY
(2020)
Review
Urology & Nephrology
Joseph M. Norris, Benjamin S. Simpson, Marina A. Parry, Clare Allen, Rhys Ball, Alex Freeman, Daniel Kelly, Hyung L. Kim, Alex Kirkham, Sungyong You, Veeru Kasivisvanathan, Hayley C. Whitaker, Mark Emberton
EUROPEAN UROLOGY OPEN SCIENCE
(2020)
Article
Urology & Nephrology
Hyung L. Kim, Eddie Mayerson, Primo N. Lara, Edward Messing, Cathy Tangen, Brian M. Shuch, Ulka Vaishampayan
EUROPEAN UROLOGY FOCUS
(2019)
Article
Biology
Jing Xian Teo, Sonia Davila, Chengxi Yang, An An Hii, Chee Jian Pua, Jonathan Yap, Swee Yaw Tan, Anders Sahlen, Calvin Woon-Loong Chin, Bin Tean Teh, Steven G. Rozen, Stuart Alexander Cook, Khung Keong Yeo, Patrick Tan, Weng Khong Lim
COMMUNICATIONS BIOLOGY
(2019)